One would expect that tumor‐targeted ICK would be less toxic and exhibit higher efficacy, but surprisingly, IL‐2‐Fc had less toxicity and equivalent antitumor efficacy compared to M5A‐IL‐2 ICK. This evidence concerns the gene IL2 and neoplasm.